
|Articles|October 15, 2003
AAO makes case for OPT for Medicare patients
Washington, DC-The Medicare Coverage Advisory Committee has voted overwhelmingly in favor of making ocular photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis) available as a valid and important treatment for treating AMD in select patients with subfoveal choroidal neovascularization (CNV) with occult but no classic CNV.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
2
EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME
3
Ophthalmic innovation by the decades: The 2010s
4
AAO 2025: When and where to find all 18 named lectures
5